chloroacetaldehyde has been researched along with Kidney Diseases in 7 studies
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The toxic metabolite of IFO thought to be responsible for IFO-induced kidney damage is chloroacetaldehyde (CAA)." | 2.45 | Ifosfamide nephrotoxicity in children: a mechanistic base for pharmacological prevention. ( Chen, N; Hanly, L; Koren, G; Rieder, M, 2009) |
| "Chloroacetaldehyde toxicity was demonstrated by the decrease in total glutathione and cellular ATP levels." | 1.36 | Targets of chloroacetaldehyde-induced nephrotoxicity. ( Baverel, G; Dubourg, L; Knouzy, B; Michoudet, C, 2010) |
| " Despite this, none of the adverse effects of 0." | 1.35 | In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro. ( Baverel, G; Dubourg, L; Michoudet, C; Yaseen, Z, 2008) |
| "Ifosfamide treatment significantly inhibited oxidative phosphorylation with only C-I substrates." | 1.33 | Ifosfamide-induced nephrotoxicity: mechanism and prevention. ( Daikhin, Y; Horyn, O; Luhovyy, B; Nissim, I; Phillips, PC; Yudkoff, M, 2006) |
| "Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO." | 1.33 | Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide nephropathy. ( Benesic, A; Freudinger, R; Gekle, M; Groezinger, F; Kirchhoff, A; Mildenberger, S; Schwerdt, G; Wollny, B, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hanly, L | 1 |
| Chen, N | 1 |
| Rieder, M | 1 |
| Koren, G | 2 |
| Knouzy, B | 1 |
| Dubourg, L | 2 |
| Baverel, G | 2 |
| Michoudet, C | 2 |
| Aleksa, K | 1 |
| Halachmi, N | 1 |
| Ito, S | 1 |
| Benesic, A | 2 |
| Schwerdt, G | 2 |
| Mildenberger, S | 2 |
| Freudinger, R | 2 |
| Gordjani, N | 1 |
| Gekle, M | 2 |
| Nissim, I | 2 |
| Horyn, O | 1 |
| Daikhin, Y | 1 |
| Luhovyy, B | 1 |
| Phillips, PC | 1 |
| Yudkoff, M | 1 |
| Groezinger, F | 1 |
| Wollny, B | 1 |
| Kirchhoff, A | 1 |
| Yaseen, Z | 1 |
1 review available for chloroacetaldehyde and Kidney Diseases
| Article | Year |
|---|---|
Ifosfamide nephrotoxicity in children: a mechanistic base for pharmacological prevention.
Topics: Acetaldehyde; Acetylcysteine; Age Factors; Antineoplastic Agents, Alkylating; Antioxidants; Child; H | 2009 |
6 other studies available for chloroacetaldehyde and Kidney Diseases
| Article | Year |
|---|---|
Targets of chloroacetaldehyde-induced nephrotoxicity.
Topics: Acetaldehyde; Adenosine Triphosphate; Animals; Biotransformation; Enzyme Inhibitors; Enzymes; Glucon | 2010 |
Renal ontogeny of ifosfamide nephrotoxicity.
Topics: Acetaldehyde; Age Factors; Animals; Antineoplastic Agents, Alkylating; Aryl Hydrocarbon Hydroxylases | 2004 |
Disturbed Ca2+-signaling by chloroacetaldehyde: a possible cause for chronic ifosfamide nephrotoxicity.
Topics: Acetaldehyde; Antineoplastic Agents, Alkylating; Calcium; Calcium Signaling; Calcium-Transporting AT | 2005 |
Ifosfamide-induced nephrotoxicity: mechanism and prevention.
Topics: Acetaldehyde; Agmatine; Animals; Antineoplastic Agents, Alkylating; Drug Interactions; Electron Tran | 2006 |
Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide nephropathy.
Topics: Acetaldehyde; Antineoplastic Agents, Alkylating; Biomarkers; Caspase 3; Caspase 8; Cathepsin B; Cell | 2006 |
In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro.
Topics: Acetaldehyde; Acetyl Coenzyme A; Adenosine Triphosphate; Amifostine; Animals; Disease Models, Animal | 2008 |